MapLight Therapeutics Inc. (MPLT)
NASDAQ: MPLTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
MPLT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $330.12M
- EPS (TTM)
- -$6.07
- Dividend yield
- None
- 52-week range
- 5.93 – 40.43
- Day range
- 5.93 – 6.48
- Volume / Avg
- 357.94K / 458.71K
- Beta
- —
- Shares outstanding
- 52.85M
- Next earnings
- Dec 3, 2026
52-week range
MPLT stock today
MapLight Therapeutics (MPLT) closed at $5.94 on Nov 20, down 7.48% (-$0.48), versus the S&P 500's 3.70% decline. Shares are 85.3% below their 52-week high of $40.43, set on Jul 10, 2026 and 0.3% above the 52-week low of $5.93, near the bottom of the past year's range. MPLT is down 66.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 57.5%.
MapLight Therapeutics has posted a net loss over the last twelve months (EPS of -$6.07), so its P/E ratio is not meaningful. The company is scheduled to report Sep/2026 results on Dec 3; analysts expect EPS of -$1.22.
Summary generated from market data by MetaCap's automated system. Methodology
About MapLight Therapeutics
Company profileMapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's disease; ML-055 for the treatment of neuropsychiatric conditions; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Christopher A. Kroeger M.B.A., M.D., Ph.D.
- Headquarters
- Redwood City, CA
- Employees
- 133
- IPO year
- 2025
- Website
- maplightrx.com
Financial highlights
Full financialsMapLight Therapeutics reported a net loss of $161.2 million, compared with a loss of $77.6 million a year earlier. Diluted earnings per share came in at -$18.56.
| Fiscal year | FY 2025 | FY 2024 |
|---|---|---|
| Revenue | — | — |
| Growth | — | — |
| Net income | $-161.15M | $-77.58M |
| EPS (diluted) | $-18.56 | $-105.38 |
Analyst forecast
ForecastConsensus (15 analysts)
strong_buy
Avg. price target
$26.15+340.24%
- Strong buy 1
- Buy 11
- Hold 3
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Dec 3, 2026
- EPS estimate
- $-1.22
- Last reported (Sep/2026)
- Dec 3, 2026
- EPS actual vs est.
- $-0.97 vs $-1.22
- Surprise
- +20.49%
MPLT news
All MPLT newsMapLight Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| INOInovio Pharmaceuticals Inc. | 1.76 | +2.92% | $329.66M | vs MPLT |
| LRMRLarimar Therapeutics Inc. | 3.14 | -2.48% | $328.55M | vs MPLT |
| CTNMContineum Therapeutics Inc. Class A | 8.68 | -3.98% | $340.83M | vs MPLT |
| AVIRAtea Pharmaceuticals Inc. | 3.96 | +0.76% | $318.00M | vs MPLT |
| PEPGPepGen Inc. | 3.78 | -3.82% | $356.31M | vs MPLT |
| ASPEAspen Neuroscience Inc. | 12.42 | +0.24% | $361.16M | vs MPLT |
| SPRYARS Pharmaceuticals Inc. | 2.96 | -11.90% | $297.56M | vs MPLT |
| PBYIPuma Biotechnology Inc | 7.05 | -0.98% | $364.47M | vs MPLT |
Indexes, lists and sector
MapLight Therapeutics stock FAQ
What is MapLight Therapeutics's stock price today?
MPLT last traded at $5.94 as of Nov 20, 4:00 PM EST, down 7.48% on the day. Prices are delayed at least 15 minutes.
When is MapLight Therapeutics's next earnings date?
MapLight Therapeutics is expected to report earnings on Thursday, December 3, 2026. Analysts expect EPS of $-1.22.
Who is MapLight Therapeutics's CEO?
Dr. Christopher A. Kroeger M.B.A., M.D., Ph.D. is the chief executive officer of MapLight Therapeutics Inc., which has about 133 employees.
What is the MPLT 52-week high?
The 52-week high for MPLT is $40.43 and the 52-week low is $5.93. The stock is currently 85.3% below its high.